Skip to Content

Tagraxofusp

Generic Name: tagraxofusp (tag RAX oh fusp)
Brand Name: Elzonris

Medically reviewed by Drugs.com on Jul 30, 2019 – Written by Cerner Multum

What is tagraxofusp?

Tagraxofusp is used to treat blastic plasmacytoid dendritic cell neoplasm, a rare blood and/or bone marrow cancer.

tagraxofusp is for use in adults and children at least 2 years old.

Tagraxofusp may also be used for purposes not listed in this medication guide.

Important Information

Call your doctor right away if you have signs of a serious side effect called capillary leak syndrome: stuffy or runny nose followed by tiredness or dizziness, thirst, decreased urination, trouble breathing, and sudden swelling or weight gain.

Before taking this medicine

You may need to have a negative pregnancy test 1 week before starting this treatment.

Tagraxofusp may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using tagraxofusp and for at least 1 week after your last dose.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

How is tagraxofusp given?

Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using tagraxofusp.

Tagraxofusp is given as an infusion into a vein. A healthcare provider will give you this injection.

You may receive this medicine in a hospital or clinic setting to quickly treat any serious side effects.

You may be given other medications to help prevent serious side effects or an allergic reaction. Keep using these medicines for as long as your doctor has prescribed.

Tagraxofusp is given in a 21-day treatment cycle. You may need to use the medicine only during the first 5 days of each cycle. Your doctor will determine how long to treat you with this medicine.

You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your cancer treatments may be delayed or permanently discontinued based on the results.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your tagraxofusp injection.

What happens if I overdose?

Since tagraxofusp is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

What should I avoid while receiving tagraxofusp?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Tagraxofusp side effects

Get emergency medical help if you have signs of an allergic reaction: hives, rash, itching; mouth sores; sudden warmth or tingly feeling; difficult breathing; swelling of your face, lips, tongue, or throat.

Capillary leak syndrome is a serious side effect of tagraxofusp. Call your doctor right away if you have a stuffy or runny nose followed by:

  • tiredness or dizziness;

  • thirst;

  • decreased urination;

  • trouble breathing; and

  • sudden swelling or weight gain.

Common side effects may include:

  • capillary leak syndrome;

  • nausea;

  • tiredness;

  • swelling in your hands or feet;

  • fever; or

  • weight gain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Tagraxofusp dosing information

Usual Adult Dose for Malignant Disease:

12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-day cycle until disease progression or unacceptable toxicity

Comments:
-Premedicate patients with an H1-histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.
-The dosing period may be extended for dose delays up to Day 10 of the cycle.

Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Usual Pediatric Dose for Malignant Disease:

2 years and older:
12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-day cycle until disease progression or unacceptable toxicity

Comments:
-Premedicate patients with an H1-histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.
-The dosing period may be extended for dose delays up to Day 10 of the cycle.

Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients 2 years and older

What other drugs will affect tagraxofusp?

Other drugs may affect tagraxofusp, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

Hide